Monoclonal antibody drugmaker United BioPharma Inc (聯合生技) yesterday said that its NT$1 billion (US$33.17 million) new plant in Hsinchu County would be able to produce 100kg of antibodies a year and satisfy the need for phase-three clinical trials and early market demand of a new drug.
The new plant will have two production lines, each with a 2,000-liter reactor, company executive director Shugene Lynn (林淑菁) said at an investors’ conference.
“We also reserved the space to build another 10 production lines for the new factory. With the extra lines, United Biopharma will be able to make 600kg of antibodies per year in the future and satisfy the demand of a new drug for the global market,” she added.
Construction is to begin by the end of this year and the factory is expected to be operational in 2016, Lynn said.
The company is developing three monoclonal antibody drug treatments and four monoclonal antibodies for use as biosimilars, company president Liao Mei-june (廖美君) said.
Among these antibodies, UB-421, which is used to treat AIDS, has completed phase-two clinical trials, while the company is to file an investigational new drug application for UB-621, which targets the Herpes simplex virus, by early next year, Liao said.
Other drugs made by the company are still in preclinical trials, she added.
United BioPharma plans to debut on the local Emerging Stock Market (興櫃市場) on Friday, with shares set at NT$85, the company said.
The debut is earlier than the time the company set in November last year.
The company will not release additional shares in its debut, said Victor Sun (孫潤本), the company’s special assistant to the chairperson.
The company’s capital is set at NT$1.15 billion, it said.
United Biomedical Inc Asia (聯亞生技), which manufactures and sells multiple medical products, owns 65 percent of United BioPharma’s shares, while Formosa Plastics Group (台塑集團), the nation’s largest industrial group, owns 25 percent, it added.
In the first half of this year, United Biopharma posted losses of NT$68.41 million, or NT$0.58 per share, because of R&D expenditures of NT$61.48 million, according to the company’s filing with the Taiwan Stock Exchange.
The company does not have comparable data for a year ago, as it was founded on Jan. 16.
Company chairperson Wang Chang-yi (王長怡) said United Biopharma plans to spend less than NT$200 million this year on R&D.
Although it has not yet reported revenue, the company expects to book licensing income next year, Wang said, without offering further information.
Semiconductor business between Taiwan and the US is a “win-win” model for both sides given the high level of complementarity, the government said yesterday responding to tariff threats from US President Donald Trump. Home to the world’s largest contract chipmaker, Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), Taiwan is a key link in the global technology supply chain for companies such as Apple Inc and Nvidia Corp. Trump said on Monday he plans to impose tariffs on imported chips, pharmaceuticals and steel in an effort to get the producers to make them in the US. “Taiwan and the US semiconductor and other technology industries
SMALL AND EFFICIENT: The Chinese AI app’s initial success has spurred worries in the US that its tech giants’ massive AI spending needs re-evaluation, a market strategist said Chinese artificial intelligence (AI) start-up DeepSeek’s (深度求索) eponymous AI assistant rocketed to the top of Apple Inc’s iPhone download charts, stirring doubts in Silicon Valley about the strength of the US’ technological dominance. The app’s underlying AI model is widely seen as competitive with OpenAI and Meta Platforms Inc’s latest. Its claim that it cost much less to train and develop triggered share moves across Asia’s supply chain. Chinese tech firms linked to DeepSeek, such as Iflytek Co (科大訊飛), surged yesterday, while chipmaking tool makers like Advantest Corp slumped on the potential threat to demand for Nvidia Corp’s AI accelerators. US stock
The US Federal Reserve is expected to announce a pause in rate cuts on Wednesday, as policymakers look to continue tackling inflation under close and vocal scrutiny from US President Donald Trump. The Fed cut its key lending rate by a full percentage point in the final four months of last year and indicated it would move more cautiously going forward amid an uptick in inflation away from its long-term target of 2 percent. “I think they will do nothing, and I think they should do nothing,” Federal Reserve Bank of St Louis former president Jim Bullard said. “I think the
Cryptocurrencies gave a lukewarm reception to US President Donald Trump’s first policy moves on digital assets, notching small gains after he commissioned a report on regulation and a crypto reserve. Bitcoin has been broadly steady since Trump took office on Monday and was trading at about US$105,000 yesterday as some of the euphoria around a hoped-for revolution in cryptocurrency regulation ebbed. Smaller cryptocurrency ether has likewise had a fairly steady week, although was up 5 percent in the Asia day to US$3,420. Bitcoin had been one of the most spectacular “Trump trades” in financial markets, gaining 50 percent to break above US$100,000 and
RSS